AstraZeneca and Rigel Sign Worldwide License Agreement for a Potential New Treatment for Chro... (d president of Discovery and Research at...)

AstraZeneca and Rigel Sign Worldwide License Agreement for a Potential New Treatment for Chronic Asthma

Date:6/19/2012

d president of Discovery and Research at Rigel Pharmaceuticals.

"We are pleased to be expanding our relationship with Rigel and to develop and commercialize this novel asset, R256," said Mene Pangalos, executive vice president of Innovative Medicines at AstraZeneca. "Despite the number of medicines available to asthma patients today, there remains a need for more targeted therapies for moderate to severe chronic asthma. Through this agreement, R256 will benefit from the wealth of experience AstraZeneca has in bringing innovative treatments for respiratory diseases to millions of patients around the world."

In preclinical studies, R256, a JAK inhibitor, has been shown to be a potent inhibitor of IL-13 and IL-4 signaling at the primary cellular level. Patients with moderate to severe chronic asthma experience persistent inflammation and cellular remodeling of their airways, which may result in permanently reduced lung function if left untreated. In preclinical models, R256 reduces the severity of inflammation and improves lung function by mechanisms associated with several hallmarks of asthma such as bronchoconstriction, mucus overproduction and airway remodeling. In May 2012, Rigel presented two studies on R256 in asthma at the American Thoracic Society International Conference.

This is the second licensing agreement between AstraZeneca and Rigel Pharmaceuticals. The companies previously announced a worldwide license agreement in February 2010, whereby AstraZeneca agreed to develop and commercialize fostamatinib, the first oral SYK inhibitor in development, as a novel therapeutic approach for rheumatoid arthritis. The Phase 3 clinical program, called OSKIRA (Oral SYK Inhibition in Rheumatoid Arthritis) enrolled its first patient in September of 2010 and is designed to investigate fostamatinib as a therapeutic option for patients who have an inadequate response to currently available therapies such as traditional disease modifyin
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Covington Advises AstraZeneca in $1.26 Billion Acquisition of Ardea Biosciences
2. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
3. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
4. Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development
5. LoneStar Heart Acquires Worldwide Exclusive Rights to New Class of Small Molecules That May Lead to New Treatments for Diabetes
6. ResearchMoz: Oxygen Concentrator Market Shares, Strategies and Forecasts, Worldwide, 2012 to 2018
7. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
8. Regulus Receives Allowance from Japan and U.S. Patent Offices for HCV Intellectual Property, Expanding Leading Worldwide Patent Estate
9. Roche Launches 454 Sequencing Assays for High Sensitivity Genetic Variant Detection in Leukemia Samples to Drive Blood Cancer Research Worldwide
10. ReproCELL Licensed Commercialization Right on Human iPS Cell Derived Hepatocytes - Expected Launch in Q2 2012
11. HistoRx Licenses Melanoma Assay from Yale University

Post Your Comments:

(Date:6/19/2013)... , June 19, 2013 Biotechnology industry pioneer ... up with financial software provider BlackLine Systems and ... SAP ) for a webinar next week entitled ... Solutions from BlackLine and SAP to Help Keep Its Account ... http://photos.prnewswire.com/prnh/20061117/LAF027LOGO ) The webinar, geared at ...

(Date:6/19/2013)... A new look at “big glass” and ... will highlight technical sessions at SPIE Photomask Technology ... 33rd year, the three-day event is the industry’s largest ... approximately 100 technical presentations and numerous networking lunches and ... optics and photonics , the meeting will be held ...

(Date:6/18/2013)... HONG KONG, June 18, 2013 China Cord ... the "Company"), China,s leading provider of cord blood collection, ... storage services, today announced its preliminary unaudited financial results ... year 2013 ended March 31, 2013. ... for the fourth quarter of fiscal 2013 increased by ...

(Date:6/18/2013)... 18, 2013 The human skin is the ... an important human body part. Similar to the liver, or ... to function, repair and grow. Recent reports from the mankatofreepress.com ... is just as important as other life supporting organs. The ... in skin cell reproduction, increase the appearance of skin, and ...

[0] Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations [0] ‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology [0] China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 [0] Natural Acne Remedies Through Diet, Probiotic Action Shares New Insight on What Foods May Help Lead to Clear Skin

... Jan. 4, 2011 Advanced Life Sciences Holdings, ... a biopharmaceutical company engaged in the discovery, development and ... infection, oncology and respiratory diseases, today announced that it ... Conference held January 10-12th in San Francisco. ...

... a biological weapon so specific, it can target an individual ... seeds of death are sown into the very blueprints of ... of us, buried deep within the human genetic code. How ... diseases? Doug Flanders ponders these very questions in ...

... Jan. 4, 2011 Reportlinker.com announces ... is available in its catalogue: ... Market: DNA Probes and Biochips New ... Strategies for Instrument and Reagent Suppliers ...

Cached Biology Technology:Advanced Life Sciences to Present at the Biotech Showcase™ 2011 Conference 2 James Bond Meets Cheaper by the Dozen: An Action Thriller the Entire Family Will Enjoy 2 Reportlinker Adds The 2011 Molecular Diagnostics Market: DNA Probes and Biochips New Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers 2

Advanced Life Sciences to Present at the Biotech Showcase™ 2011 Conference James Bond Meets Cheaper by the Dozen: An Action Thriller the Entire Family Will Enjoy Reportlinker Adds The 2011 Molecular Diagnostics Market: DNA Probes and Biochips New Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers

(Date:6/19/2013)... provider of scientific, technical and medical information products and ... new open access journal, GeoResJ . , ... and planetary science journals portfolio has its first open ... forum for rapid publication of top research within the ... by six Executive Editors, each covering a different discipline, ...

(Date:6/18/2013)... UT Arlington environmental engineer has been awarded a ... to ensure water quality and flow in the ... , Andrew Kruzic, UT Arlington associate professor of ... locations to add monochloramine to the water in ... new pump stations and pipelines. Adding monochloramine is ...

(Date:6/18/2013)... $12.7 million to match nine academic research groups ... explore new treatments for patients in eight disease ... schizophrenia. The collaborative pilot initiative, called Discovering New ... the National Center for Advancing Translational Sciences (NCATS) ... The process of developing a new therapeutic is ...

Breaking Biology News(10 mins):UT Arlington research to benefit quality, flow in 150-mile Integrated Pipeline 2 NIH to fund collaborations with industry to identify new uses for existing compounds 2 NIH to fund collaborations with industry to identify new uses for existing compounds 3 NIH to fund collaborations with industry to identify new uses for existing compounds 4

[0] Elsevier launches open access journal: GeoResJ [0] UT Arlington research to benefit quality, flow in 150-mile Integrated Pipeline [0] NIH to fund collaborations with industry to identify new uses for existing compounds

... A Century of Change, literally took 100 years to write. ... from 1906-1909. It was repeated from 1956-1958 and a technical ... anniversary of that first survey was approaching, ornithologists Mike Ward, ... of opportunity to do it again and write a book, ...

... the United States and Japan analyzed fossil evidence found ... horned dinosaur. The newly identified genus, Koreaceratops ... the late Early Cretaceous period. The specimen is ... The partial skeleton includes a significant portion of the ...

... social stress activates the immune system and accelerates the ... pressure, however, may stop this process. This is the ... Gothenburg, Sweden. Several large studies have clearly shown ... the risk of developing cardiovascular disease. However, little is ...

Cached Biology News:New book on 100 years of Illinois birds 2 New book on 100 years of Illinois birds 3 New book on 100 years of Illinois birds 4 Scientists announce discovery of first horned dinosaur from South Korea 2 Social stress leads to atherosclerosis 2

New book on 100 years of Illinois birds Scientists announce discovery of first horned dinosaur from South Korea Social stress leads to atherosclerosis

...

UltraPure DNase/RNase-Free Distilled Water is designed for use in all molecular biology applications. It is 0.1-m membrane-filtered and tested for DNase and RNase activity....

...

Water Distilled (Gibco™) is membrane filtered and endotoxin screened....

Biology Products:

Polyvalent HRP AEC Detection System from Spring Bioscience UltraPure DNase/RNase-Free Distilled Water from Invitrogen Luminex 100 IS System from Luminex Corporation GIBCO Water distilled from Invitrogen